Skip to content
Evigrade
CriticalSelective serotonin reuptake inhibitors (SSRIs)×Reversible MAO-A inhibitor (RIMA)

Updated · Methodology

Mechanism

Moclobemide reversibly inhibits monoamine oxidase (MAO), mainly type A, and slows the breakdown of noradrenaline, dopamine and serotonin (moclobemide summary of product characteristics, SmPC, section 5.1). Escitalopram is a selective serotonin reuptake inhibitor (escitalopram SmPC, section 5.1). The Spanish escitalopram SmPC contraindicates it with reversible MAO type A inhibitors such as moclobemide because of the risk of serotonin syndrome (section 4.3). In the liver, the cytochrome P450 (CYP) enzyme CYP2C19 breaks down most of the escitalopram, and CYP3A4 and CYP2D6 contribute less (escitalopram SmPC, sections 4.5 and 5.2). Moclobemide inhibits CYP2C19 (moclobemide SmPC, section 4.5). The SmPCs give no figures for this pair, but with another CYP2C19 inhibitor, omeprazole 30 mg once daily, escitalopram concentrations rose by about 50% (escitalopram SmPC, section 4.5). CYP2C19 and CYP2D6 also take part in moclobemide metabolism. Escitalopram inhibits CYP2D6 and, in vitro, slightly inhibits CYP2C19, but moclobemide has alternative metabolic pathways, and such effects generally do not call for a dose change (escitalopram SmPC, section 4.5, and moclobemide SmPC, section 5.2).

Symptoms

A combination of agitation, tremor, muscle jerks (myoclonus) and high temperature may indicate serotonin syndrome (escitalopram summary of product characteristics, SmPC, sections 4.3 and 4.4). When moclobemide was combined with other antidepressants, including escitalopram, isolated cases of a severe combination of high temperature, confusion, overactive reflexes (hyperreflexia) and myoclonus occurred (moclobemide SmPC, section 4.5). According to the US Food and Drug Administration (FDA) escitalopram label, serotonin syndrome may present with agitation, hallucinations, delirium and coma, fast heart rate, labile blood pressure, dizziness, sweating, flushing and high temperature, tremor, muscle rigidity, myoclonus, hyperreflexia, poor coordination, seizures, nausea, vomiting and diarrhoea (section 5.2).

Management

The combination is contraindicated. The Spanish escitalopram summary of product characteristics (SmPC) contraindicates escitalopram with reversible monoamine oxidase (MAO) type A inhibitors and names moclobemide (sections 4.3 and 4.5). The US Food and Drug Administration (FDA) escitalopram label contraindicates it with any MAO inhibitor (sections 4 and 7). The moclobemide SmPC is less strict and advises caution when escitalopram and other antidepressants that raise serotonin are given with moclobemide (section 4.5). If the combination is nevertheless necessary, the Spanish escitalopram SmPC advises starting at the lowest recommended dose with closer clinical monitoring (section 4.5). When switching from escitalopram to moclobemide, take the half-life of escitalopram into account (moclobemide SmPC, section 4.5). It is about 30 hours, and the main metabolites have a much longer half-life (escitalopram SmPC, section 5.2). According to the moclobemide SmPC, another antidepressant can be started the day after moclobemide is stopped (section 4.5). According to the FDA escitalopram label, at least 14 days should pass between an MAO inhibitor used for psychiatric disorders and escitalopram, in either direction (sections 2.7 and 4). If the two drugs are nevertheless taken together, bear in mind that moclobemide inhibits CYP2C19, a cytochrome P450 enzyme (moclobemide SmPC, section 4.5). Prescribe escitalopram with caution alongside CYP2C19 inhibitors, and lower its dose if adverse effects call for it (escitalopram SmPC, section 4.5). If signs of serotonin syndrome appear, stop escitalopram and other serotonergic drugs immediately and start symptomatic treatment (escitalopram SmPC, section 4.4, and FDA escitalopram label, section 5.2). The moclobemide SmPC advises considering a lower moclobemide dose or stopping it, depending on how severe the symptoms are (section 4.4). If high temperature, confusion, hyperreflexia and myoclonus occur together, keep the patient under medical observation, in hospital if needed (moclobemide SmPC, section 4.5).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Escitalopram

Other interactions with Moclobemide